RxRecall / Maher Law Firm
Isradipine Recalled
Dow Jones Newswires (2/25, Loftus, Subscription Publication) reported that on Friday, GlaxoSmithKline PLC voluntarily recalled more than 394,200 bottles of isradipine because of a potential tablet mix up at Novartis AG. U.K.-based Glaxo said Friday “it issued the voluntary recall of all bottles of [DynaCirc] remaining in the U.S. market from wholesalers, pharmacies and hospitals. GSK spokesman Kevin Colgan said that “because of the recall, the medication will not be available to patients.”
